A Phase 1/2 interventional study of SAGE-547 in Super-refractory Status Epilepticus, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 17 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Supernus Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Status Epilepticus with a site in United States — 13 open to participants now, 13 under way, 2 of them phase 3. Status Epilepticus · United States.
Among the 41 studies in Status Epilepticus with a site in United States, this one is the 17th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2014, is the only one in phase 1/2, and was the 8th registered.
124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.
Browse Status Epilepticus studies →13 of the 41 studies in Status Epilepticus with a site in United States are open now. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 1+
Boston Medical Center · Sites in United States
Ages 21+
University of California, San Francisco · Sites in United States
Ages 18+
Nationwide Children's Hospital · Sites in United States
Ages 30 days–18 yrs
University of California, San Francisco · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 29 Status Epilepticus studies recruiting now, 16 (55%) set no upper age limit and 8 (28%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 11 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 80 across 75 interventional studies indexed under Status Epilepticus.
Median enrollment 35 across the 30 interventional studies, 300 across the 11 observational. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 41 have an industry lead sponsor. The 10 most frequent:
Supernus Pharmaceuticals, Inc. is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
Supernus Pharmaceuticals, Inc. has 3 studies filed under Status Epilepticus — fewer than ten, so there is no comparison to draw.
5 of the studies in Status Epilepticus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06564662Children's Hospital at MontefioreRapid-Response EEG in Children With Suspected Status Epilepticus | 2026-12-08 |
| NCT06194747Nationwide Children's HospitalImproving Status Epilepticus Treatment Times | 2027-03-31 |
| NCT06401707University of California, San FranciscoPeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest | 2027-05-20 |
| NCT07177235Thomas Jefferson UniversityKetamine for the Treatment of Refractory Status Epilepticus | 2027-07 |
| NCT05851391University of California, San FranciscobuRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 41 studies in Status Epilepticus with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).
This is an open-label study consisting of a screening period (1 day), 4-day treatment period (96 hours) followed by a 1-day dose taper period (24 hours), a 2-day acute follow-up period, and a 3 week extended follow-up period.
On Day 1 of treatment SRSE participants under seizure suppression or burst-suppression with a continuous intravenous (IV) anti-epileptic drug (AED) (third-line agent) were given a 1-hour IV loading infusion of SAGE-547 followed by a maintenance infusion. After 48 hours of SAGE-547 treatment, the continuous IV AED (third-line agent) was weaned while continuing SAGE-547 at the maintenance infusion for the remainder of the treatment period. After 96 hours (4 days) of therapy with SAGE-547, the dose was to be tapered and discontinued over 24 hours.
The participants would have routine continuous electroencephalogram (EEG) monitoring during the screening period, and continuing until 48 hours after SAGE-547 treatment had completed. Participants would then have follow-up examinations weekly for the next 3 weeks (Days 8, 15, 22, and 29), during which safety and functional assessments would be obtained. Apart from treatment with SAGE-547, all participants would receive the standard of care for adults in SRSE along with ongoing treatment for all underlying medical conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with an EEG-confirmed SRSE diagnosis under concomitant therapy with a continuous IV AED ( agent) for ≥ 24 hours. For this study, SRSE is defined by the following criteria and in accordance with those used at major epilepsy treatment centers:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received SAGE-547 IV loading infusion of 286.6 micrograms per kilogram per hour (μg/kg/hr) for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5.
Drug: SAGE-547
Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5.
Drug: SAGE-547
Solution for injection for IV infusion
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAEs are defined as those that begin on or after initiation of the infusion of SAGE-547.
Time frame: Up to Day 29
Change From Baseline (CFB) in National Institutes of Health Stroke Scale (NIH-SS) Total Score
The National Institutes of Health Stroke Scale (NIH-SS) was used to examine the physical and neurological state of the participants. The NIH-SS is a 15-item assessment with measures of level of consciousness, visual gaze and vision loss, facial palsy, motor ability, ataxia, sensory ability, aphasia, dysarthria, and inattention. The total NIHSS score range is from 0 (normal) to 42 (severe impairment), with higher values indicating greater level of neurological impairment.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Vital Sign Parameter: Body Weight
Vital signs included weight, heart rate, blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)), respiratory rate, temperature, oxygen saturation. CFB in body weight is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Vital Sign Parameter: Heart Rate
Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in heart rate is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended Follow-up at Days 8, 15, 22 and 29
Change From Baseline in Vital Sign Parameter: Blood Pressure - SBP and DBP
Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in SBP and DBP is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24 hours:Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72: 72 hour;73-96: 96 hour;97-120:120 hour;Acute follow-up at 121-144,145-168 hours;Extended follow-up at Days 8,15,22 and 29
Change From Baseline in Vital Sign Parameter: Respiratory Rate
Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in respiratory rate is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24 hours:Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours;Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Vital Sign Parameter: Body Temperature
Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in body temperature is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Vital Sign Parameter: Oxygen Saturation
Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. Oxygen saturation is a measure of how much hemoglobin is currently bound to oxygen compared to how much hemoglobin remains unbound. CFB in oxygen saturation is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Alanine Aminotransferase Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in alanine aminotransferase levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Albumin Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in albumin levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Aspartate Aminotransferase Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in aspartate aminotransferase levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Bicarbonate Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in bicarbonate levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Bilirubin Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in bilirubin levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Blood Urea Nitrogen Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in blood urea nitrogen levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Calcium Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in calcium levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Chloride Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in chloride levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Creatine Kinase Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in creatine kinase levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Creatinine Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in creatinine levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Glucose Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in glucose levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Lipase Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in lipase levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Magnesium Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in magnesium levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Potassium Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in potassium levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Protein Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in protein levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Serum Chemistry Parameter: Sodium Levels
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in sodium levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Basophil Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in basophil levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Basophils to Leukocytes Ratio Reported in Percentage of Cells
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in basophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Eosinophil Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in eosinophils levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Eosinophils to Leukocytes Ratio Reported in Percentage of Cells
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in eosinophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Concentration Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular hemoglobin concentration levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular hemoglobin levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular volume levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Erythrocyte Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocyte levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Hematocrit Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in hematocrit levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Hemoglobin Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in hemoglobin levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Leukocyte Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in leukocyte levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Lymphocyte Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in lymphocyte levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Lymphocytes to Leukocytes Ratio Reported in Percentage of Cells
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in lymphocytes to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Monocyte Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in monocyte levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Monocytes to Leukocytes Ratio Reported in Percentage of Cells
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in monocytes to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Neutrophil Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in neutrophil levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Neutrophils to Leukocytes Ratio Reported in Percentage of Cells
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in neutrophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Hematology Parameter: Platelet Levels
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in platelet levels is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Electrocardiogram (ECG) Parameter: Heart Rate
ECG measures included heart rate, PR interval, QT interval, QRS duration and QTc interval. CFB in heart rate is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Interval, QT Interval and QTc Interval
ECG measures included heart rate, PR interval, QT interval, QRS duration and QTc interval. CFB in PR interval, QT interval, QRS duration and QTc interval is reported in this outcome measure.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Number of Participants With Prior Anti-epileptic Drugs (AEDs) and Pressors Usage
Prior AEDs and Pressors are those medications that ended before the initiation of SAGE-547 infusion.
Time frame: Up to Day 29
Number of Participants With Relapse - Re-Initiation of Third-Line Agent
Relapse of participants is defined as successfully weaning from a continuous IV third-line agent but subsequent requirement of re-initiation of a third-line agent following conclusion of SAGE-547 treatment.
Time frame: Up to Day 29
Number of Participants With Treatment Response (Treatment Responders)
A responder was defined as a participant for whom it was not required to re-initiate continuous IV third-line therapy for refractory seizure control during the administration of SAGE-547 at the maintenance dose (prior to SAGE-547 taper infusion).
Time frame: Up to 96 hours
Duration of Response
Duration of response was defined as the time from the stop date/time of SAGE-547 maintenance to re-initiation of a third-line agent. If no re-initiation of a third-line agent was required, duration of response was not estimable and censored at Day 29 or death date, whichever occurred first. Kaplan-Meier method was used for the analysis.
Time frame: Up to Day 29
Maximum Plasma Concentration (Cmax) of SAGE-547
Time frame: Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose
Time to Attain Maximum Observed Plasma Concentration (Tmax) of SAGE-547
Time frame: Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose
Areas Under the Plasma SAGE-547 Concentration Time Curves From the Start of the Infusion Until the Time to the Last Sample (AUClast)
Time frame: Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose
Area Under the Plasma SAGE-547 Concentration-Time Curve in a 24 Hour Period (AUC24)
Time frame: Pre-dose (0 hours), 1, 2, 4, 8 and 24 hours post-dose
Area Under the Plasma SAGE-547 Concentration-Time Curve (AUC1-96)
Time frame: Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose
Average Plasma Concentration (Cav) of SAGE-547
Time frame: Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose
Plasma Clearance (CL) of SAGE-547
Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.
Time frame: Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose
Change From Baseline in Modified Rankin Scale (mRS-9Q) Scores
The mRS-9Q is a commonly used scale to determine disability and functional dependence due to neurological insult such as a stroke. It is a shortened version consisting of 9 questions. The score was categorized on the scale of 0 to 5 (0 = No symptoms, 1 = No significant disability, able to carry out all usual activities, despite some symptoms, 2 = Slight disability, able to look after own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability, requires some help, but able to walk unassisted, 4 = Moderately severe disability, unable to attend to own bodily needs without assistance or unable to walk unassisted, and 5 = Severe disability, requires constant nursing care and attention, bedridden). Higher scores indicated worsening of symptoms.
Time frame: Baseline (Screening) to Infusion at 49-72 hour, 73-96 hour; Extended follow-up at Day 8, 15, 22 and 29
Change From Baseline in Clinical Global Impression: Severity Scale (CGI-S)
The CGI-Severity (CGI-S) scale employs a 7-point Likert scale to assess the severity of participant's current illness state. Clinician responded to a question "Considering your total clinical experience with this particular population, how mentally ill is your patient at this time?" on the following scores: 1 = Normal, not at all ill, 2 = Borderline ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, and 7 = Among the most extremely ill, where higher score = more affected.
Time frame: Baseline (Screening), Extended follow-up at Days 8, 15, 22, and 29
Clinical Global Impression: Improvement Scale (CGI-I) Scores
The CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse; where higher scores indicated worst outcomes. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions.
Time frame: Infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Glasgow Coma Scale (GCS) Scores
The Glasgow Coma Scale is divided into three components which are scored separately: ocular response (assessment 1-4 points), motor response (assessment 1-6 points), verbal response (evaluation of 1-5 points). Scores for each component are added together to get the total score that will range between a minimum of 3 points (which corresponds to a participant who does not open his/her eyes and no motor response to stimulation or verbal response) and a maximum value of 15 points (corresponding to a participant with open eyes, obeying orders and maintaining a consistent language). It has been considered that the GCS score between 15 and 13 points corresponds to a slight alteration of consciousness, a score of 12-9 points with moderate impairment and 8 points or less with a serious deterioration in level of consciousness.
Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Change From Baseline in Richmond Agitation Sedation Scale (RASS) Score
The RASS was an assessment of agitation and sedation in hospitalized participants, using a 10 point scale (ranged from -5 to +4), where, -5 = Unarousable, -4 = Deep sedation, -3 = Moderate sedation, -2 = Light sedation, -1 = Drowsy, 0 = Alert and calm, +1 = Restless, +2 = Agitated, +3 = Very agitated and +4 = Combative. Lower scores signify higher levels of sedation and higher scores signify heightened agitation. Participant in a calm and alert state would score a 0.
Time frame: Baseline (Screening) to Infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Number of Participants Who Survived
Survival time was defined as duration of survival from screening up to Day 29.
Time frame: Up to Day 29
Participants took part in the study at 12 sites in United States from 21 March 2014 to 03 May 2015.
| Milestone | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Started | 19 | 6 |
| Completed | 14 | 5 |
| Not completed | 5 | 1 |
| Withdrew: Withdrew due to adverse event | 3 | 0 |
| Withdrew: Participant died | 2 | 1 |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAEs are defined as those that begin on or after initiation of the infusion of SAGE-547.
| Participants | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 17 | 6 |
The National Institutes of Health Stroke Scale (NIH-SS) was used to examine the physical and neurological state of the participants. The NIH-SS is a 15-item assessment with measures of level of consciousness, visual gaze and vision loss, facial palsy, motor ability, ataxia, sensory ability, aphasia, dysarthria, and inattention. The total NIHSS score range is from 0 (normal) to 42 (severe impairment), with higher values indicating greater level of neurological impairment.
| score on a scale | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 34.2 ± 4.69 | 33.0 ± 4.86 |
| CFB at Infusion: 0-24 hours | 0.7 ± 2.30 | 0.3 ± 1.51 |
| CFB at Infusion: 25-48 hours | 0.8 ± 3.47 | -1.5 ± 6.19 |
| CFB at Infusion: 49-72 hours | -2.2 ± 6.70 | -2.3 ± 4.63 |
| CFB at Infusion: 73-96 hours | -2.9 ± 8.08 | -5.5 ± 6.63 |
| CFB at Infusion: 97-120 hours | -5.6 ± 7.44 | -6.7 ± 7.20 |
| CFB at Acute Follow-up: 121-144 hours | -7.0 ± 8.75 | -10.8 ± 10.13 |
| CFB at Acute Follow-up: 145-168 hours | -7.5 ± 9.78 | -12.0 ± 8.76 |
| CFB at Extended Follow-up: Day 8 | -9.0 ± 9.54 | -15.4 ± 11.82 |
| CFB at Extended Follow-up: Day 15 | -16.8 ± 12.10 | -16.6 ± 13.30 |
| CFB at Extended Follow-up: Day 22 | -15.1 ± 14.35 | -17.2 ± 14.55 |
| CFB at Extended Follow-up: Day 29 | -16.7 ± 15.34 | -20.6 ± 13.09 |
Vital signs included weight, heart rate, blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)), respiratory rate, temperature, oxygen saturation. CFB in body weight is reported in this outcome measure.
| kilograms (kg) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 78.263 ± 25.3905 | 81.667 ± 20.3141 |
| CFB at Infusion: 0-24 hours | 0.253 ± 3.3321 | 0.250 ± 0.3987 |
| CFB at Infusion: 25-48 hours | 1.095 ± 3.9392 | 1.083 ± 2.1424 |
| CFB at Infusion: 49-72 hours | 1.444 ± 3.5787 | -0.933 ± 2.9561 |
| CFB at Infusion: 73-96 hours | 1.517 ± 4.5509 | -0.033 ± 4.4275 |
| CFB at Infusion: 97-120 hours | 0.688 ± 4.3148 | 1.567 ± 8.8672 |
| CFB at Acute Follow-up: 121-144 hours | -0.631 ± 6.3734 | 1.650 ± 12.6751 |
| CFB at Acute Follow-up: 145-168 hours | -0.930 ± 7.7080 | -5.100 ± 4.8298 |
| CFB at Extended Follow-up: Day 8 | 0.436 ± 9.5258 | -1.720 ± 7.6392 |
| CFB at Extended Follow-up: Day 15 | -0.708 ± 10.1362 | -6.100 ± 4.7589 |
| CFB at Extended Follow-up: Day 22 | 0.644 ± 8.9288 | -3.420 ± 12.4474 |
| CFB at Extended Follow-up: Day 29 | -6.130 ± 13.5243 | 0.108 ± 19.4907 |
Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in heart rate is reported in this outcome measure.
| beats per minute (beats/min) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 89.3 ± 14.33 | 81.8 ± 20.90 |
| CFB at Infusion: 0-24 hours: Loading - Pre-Dose | -2.3 ± 4.65 | -0.5 ± 2.12 |
| CFB at Infusion: 0-24 hours: Loading - 15 minutes | -0.7 ± 3.36 | 0.6 ± 1.52 |
| CFB at Infusion: 0-24 hours: Loading - 30 minutes | 0.2 ± 5.26 | -2.0 ± 2.45 |
| CFB at Infusion: 0-24 hours: Loading - 45 minutes | -0.9 ± 3.98 | -3.6 ± 4.10 |
| CFB at Infusion: 0-24 hours: 1 hour | -1.3 ± 4.18 | -4.7 ± 7.26 |
| CFB at Infusion: 0-24 hours: 2 hours | -1.6 ± 4.92 | -0.5 ± 7.56 |
| CFB at Infusion: 0-24 hours: 4 hours | -0.6 ± 7.65 | -2.8 ± 8.52 |
| CFB at Infusion: 0-24 hours: 8 hours | -3.5 ± 9.87 | -10.7 ± 10.07 |
| CFB at Infusion: 0-24 hours: 24 hours | -2.2 ± 13.52 | 1.8 ± 7.11 |
| CFB at Infusion: 25-48 hours: 48 hours | 1.9 ± 15.09 | -4.8 ± 8.04 |
| CFB at Infusion: 49-72 hours: 72 hours | 5.4 ± 13.65 | 2.7 ± 12.42 |
| CFB at Infusion: 73-96 hours: 96 hours | 6.8 ± 14.03 | 8.0 ± 14.38 |
| CFB at Infusion: 97-120 hours: 120 hours | 12.9 ± 13.43 | 10.7 ± 28.86 |
| CFB at Acute Follow-up: 121-144 hours | 10.1 ± 13.10 | 18.0 ± 23.33 |
| CFB at Acute Follow-up: 145-168 hours | 10.9 ± 15.77 | 14.8 ± 17.17 |
| CFB at Extended Follow-up: Day 8 | 11.8 ± 12.69 | 5.6 ± 15.34 |
| CFB at Extended Follow-up: Day 15 | 12.8 ± 15.66 | 6.0 ± 12.63 |
| CFB at Extended Follow-up: Day 22 | 13.3 ± 11.92 | 13.6 ± 27.88 |
| CFB at Extended Follow-up: Day 29 | 9.5 ± 16.19 | 11.2 ± 26.54 |
Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in SBP and DBP is reported in this outcome measure.
| millimeters of mercury (mmHg) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| SBP Baseline | 111.1 ± 14.55 | 111.8 ± 7.46 |
| SBP CFB at Infusion: 0-24 hours: Loading - Pre-Dose | 1.3 ± 13.23 | 20.0 ± 28.28 |
| SBP CFB at Infusion: 0-24 hours: Loading - 15 minutes | -3.2 ± 8.36 | 5.0 ± 11.85 |
| SBP CFB at Infusion: 0-24 hours: Loading - 30 minutes | -4.3 ± 12.64 | 3.8 ± 11.12 |
| SBP CFB at Infusion: 0-24 hours: Loading - 45 minutes | -5.3 ± 12.55 | -9.4 ± 12.22 |
| SBP CFB at Infusion: 0-24 hours: 1 hour | -7.4 ± 11.96 | -6.8 ± 11.39 |
| SBP CFB at Infusion: 0-24 hours: 2 hours | -6.1 ± 15.96 | -5.7 ± 19.72 |
| SBP CFB at Infusion: 0-24 hours: 4 hours | -1.1 ± 14.40 | -1.7 ± 11.81 |
| SBP CFB at Infusion: 0-24 hours: 8 hours | -5.1 ± 18.55 | -1.3 ± 18.02 |
| SBP CFB at Infusion: 0-24 hours: 24 hour | -5.6 ± 19.26 | 5.7 ± 17.63 |
| SBP CFB at Infusion: 25-48 hours: 48 hours | -3.1 ± 21.49 | 2.5 ± 21.55 |
| SBP CFB at Infusion: 49-72 hours: 72 hours | -2.1 ± 27.72 | 3.0 ± 23.83 |
| SBP CFB at Infusion: 73-96 hours: 96 hours | 6.2 ± 24.06 | 11.8 ± 24.39 |
| SBP CFB at Infusion: 97-120 hours: 120 hours | -6.9 ± 22.13 | -1.8 ± 21.04 |
| SBP CFB at Acute Follow-up: 121-144 hours | -2.2 ± 18.67 | 12.8 ± 21.58 |
| SBP CFB at Acute Follow-up: 145-168 hours | -0.2 ± 24.46 | 7.0 ± 25.93 |
| SBP CFB at Extended Follow-up: Day 8 | -0.9 ± 21.12 | 5.0 ± 16.02 |
| SBP CFB at Extended Follow-up: Day 15 | 8.9 ± 19.55 | 3.2 ± 11.52 |
| SBP CFB at Extended Follow-up: Day 22 | 1.6 ± 27.60 | 7.0 ± 6.75 |
| SBP CFB at Extended Follow-up: Day 29 | 2.0 ± 24.20 | 2.8 ± 19.77 |
| DBP Baseline | 59.7 ± 8.51 | 60.8 ± 10.69 |
| DBP CFB at Infusion: 0-24 hours: Loading - Pre-Dose | 1.3 ± 10.53 | 7.5 ± 10.61 |
| DBP CFB at Infusion: 0-24 hours: Loading - 15 minutes | -2.1 ± 5.83 | 2.2 ± 4.15 |
| DBP CFB at Infusion: 0-24 hours: Loading - 30 minutes | -2.6 ± 10.38 | 3.6 ± 5.41 |
| DBP CFB at Infusion: 0-24 hours: Loading - 45 minutes | -3.3 ± 6.26 | -3.6 ± 7.33 |
| DBP CFB at Infusion: 0-24 hours: 1 hour | -3.4 ± 8.17 | -1.8 ± 3.25 |
| DBP CFB at Infusion: 0-24 hours: 2 hours | -2.8 ± 6.70 | -3.2 ± 9.56 |
| DBP CFB at Infusion: 0-24 hours: 4 hours | -1.7 ± 7.36 | 0.0 ± 8.67 |
| DBP CFB at Infusion: 0-24 hours: 8 hours | -2.5 ± 7.11 | -5.0 ± 12.17 |
| DBP CFB at Infusion: 0-24 hours: 24 hours | -2.9 ± 12.61 | 6.3 ± 24.99 |
| DBP CFB at Infusion: 25-48 hours: 48 hours | -2.9 ± 9.01 | -4.0 ± 7.87 |
| DBP CFB at Infusion: 49-72 hours: 72 hours | -1.2 ± 16.37 | -4.2 ± 5.42 |
| DBP CFB at Infusion: 73-96 hours: 96 hours | 1.1 ± 12.09 | 3.3 ± 7.58 |
| DBP CFB at Infusion: 97-120 hours: 120 hours | -3.4 ± 12.65 | 1.0 ± 12.13 |
| DBP CFB at Acute Follow-up: 121-144 hours | -1.8 ± 11.53 | 6.6 ± 8.99 |
| DBP CFB at Acute Follow-up: 145-168 hours | 0.8 ± 18.15 | 3.0 ± 18.59 |
| DBP CFB at Extended Follow-up: Day 8 | 1.1 ± 12.40 | 1.0 ± 10.89 |
| DBP CFB at Extended Follow-up: Day 15 | 7.9 ± 11.13 | 4.8 ± 6.22 |
| DBP CFB at Extended Follow-up: Day 22 | 7.3 ± 14.67 | 13.4 ± 11.72 |
| DBP CFB at Extended Follow-up: Day 29 | 7.9 ± 11.02 | 12.4 ± 22.78 |
Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in respiratory rate is reported in this outcome measure.
| breaths per min (breaths/min) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 17.4 ± 4.66 | 13.4 ± 3.58 |
| CFB at Infusion: 0-24 hours: Loading - Pre-Dose | 0.3 ± 2.75 | -2.0 ± 1.41 |
| CFB at Infusion: 0-24 hours: Loading - 15 minutes | 0.2 ± 2.39 | -0.6 ± 0.89 |
| CFB at Infusion: 0-24 hours: Loading - 30 minutes | -0.3 ± 3.05 | -1.0 ± 1.41 |
| CFB at Infusion: 0-24 hours: Loading - 45 minutes | -0.3 ± 2.64 | 1.0 ± 2.65 |
| CFB at Infusion: 0-24 hours: 1 hour | 0.2 ± 2.24 | 0.2 ± 1.47 |
| CFB at Infusion: 0-24 hours: 2 hours | 1.1 ± 2.78 | 0.8 ± 1.33 |
| CFB at Infusion: 0-24 hours: 4 hours | 0.6 ± 1.98 | -0.2 ± 1.33 |
| CFB at Infusion: 0-24 hours: 8 hours | -0.5 ± 2.14 | -0.3 ± 1.86 |
| CFB at Infusion: 0-24 hours: 24 hours | 0.3 ± 4.08 | 0.7 ± 1.51 |
| CFB at Infusion: 25-48 hours: 48 hours | -0.1 ± 3.21 | -0.8 ± 3.66 |
| CFB at Infusion: 49-72 hours: 72 hours | 1.6 ± 3.65 | 1.0 ± 6.96 |
| CFB at Infusion: 73-96 hours: 96 hours | 4.7 ± 6.87 | 1.2 ± 6.97 |
| CFB at Infusion: 97-120 hours: 120 hours | 2.5 ± 5.62 | 1.0 ± 4.90 |
| CFB at Acute Follow-up: 121-144 hours | 3.2 ± 4.25 | 1.4 ± 5.77 |
| CFB at Acute Follow-up: 145-168 hours | 4.2 ± 6.08 | 6.0 ± 6.32 |
| CFB at Extended Follow-up: Day 8 | 4.3 ± 5.94 | 0.6 ± 3.05 |
| CFB at Extended Follow-up: Day 15 | 3.7 ± 5.87 | 5.0 ± 6.40 |
| CFB at Extended Follow-up: Day 22 | 4.9 ± 4.32 | 3.0 ± 6.00 |
| CFB at Extended Follow-up: Day 29 | 3.5 ± 6.35 | 5.6 ± 11.28 |
Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in body temperature is reported in this outcome measure.
| degrees Fahrenheit (F) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 99.21 ± 1.195 | 98.98 ± 2.312 |
| CFB at Infusion: 0-24 hours: Loading - Pre-Dose | -0.80 ± 0.883 | -0.30 ± 0.707 |
| CFB at Infusion: 0-24 hours: Loading - 15 minutes | -0.38 ± 0.471 | -0.04 ± 0.329 |
| CFB at Infusion: 0-24 hours: Loading - 30 minutes | -0.54 ± 0.628 | -0.14 ± 0.371 |
| CFB at Infusion: 0-24 hours: Loading - 45 minutes | -0.58 ± 0.662 | -0.32 ± 0.432 |
| CFB at Infusion: 0-24 hours: 1 hour | -0.51 ± 0.614 | -0.55 ± 0.468 |
| CFB at Infusion: 0-24 hours: 2 hours | -0.44 ± 0.902 | -0.48 ± 0.407 |
| CFB at Infusion: 0-24 hours: 4 hours | -0.17 ± 1.269 | -0.47 ± 0.596 |
| CFB at Infusion: 0-24 hours: 8 hours | -0.74 ± 1.361 | -0.52 ± 0.985 |
| CFB at Infusion: 0-24 hours: 24 hours | -0.20 ± 1.704 | 0.20 ± 1.474 |
| CFB at Infusion: 25-48 hours: 48 hours | -0.51 ± 1.467 | -0.47 ± 1.335 |
| CFB at Infusion: 49-72 hours: 72 hours | -0.53 ± 1.522 | -0.47 ± 1.296 |
| CFB at Infusion: 73-96 hour: 96 hours | -0.32 ± 1.263 | -0.62 ± 1.283 |
| CFB at Infusion: 97-120 hours: 120 hours | -0.14 ± 1.230 | -0.92 ± 1.514 |
| CFB at Acute Follow-up: 121-144 hours | 0.06 ± 1.360 | -0.16 ± 1.450 |
| CFB at Acute Follow-up: 145-168 hours | -0.29 ± 1.896 | -0.20 ± 0.652 |
| CFB at Extended Follow-up: Day 8 | 0.03 ± 1.010 | -0.46 ± 0.684 |
| CFB at Extended Follow-up: Day 15 | -0.44 ± 1.852 | -0.42 ± 0.740 |
| CFB at Extended Follow-up: Day 22 | -0.62 ± 1.834 | -0.96 ± 1.790 |
| CFB at Extended Follow-up: Day 29 | -0.69 ± 1.515 | -1.20 ± 2.164 |
Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. Oxygen saturation is a measure of how much hemoglobin is currently bound to oxygen compared to how much hemoglobin remains unbound. CFB in oxygen saturation is reported in this outcome measure.
| percentage of oxygen saturation | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 98.8 ± 2.26 | 98.6 ± 1.67 |
| CFB at Infusion: 0-24 hours: Loading - Pre-Dose | 0.0 ± 0.00 | 0.5 ± 0.71 |
| CFB at Infusion: 0-24 hours: Loading - 15 minutes | 0.0 ± 0.33 | 0.2 ± 0.45 |
| CFB at Infusion: 0-24 hours: Loading - 30 minutes | -0.3 ± 1.45 | 0.4 ± 1.52 |
| CFB at Infusion: 0-24 hours: Loading - 45 minutes | -0.2 ± 1.08 | 0.2 ± 1.92 |
| CFB at Infusion: 0-24 hours: 1 hour | -0.5 ± 2.48 | 0.0 ± 1.55 |
| CFB at Infusion: 0-24 hours: 2 hours | 0.1 ± 1.10 | -1.3 ± 4.76 |
| CFB at Infusion: 0-24 hours: 4 hours | -0.2 ± 0.69 | 1.2 ± 1.33 |
| CFB at Infusion: 0-24 hours: 8 hours | -0.1 ± 1.45 | 1.0 ± 0.89 |
| CFB at Infusion: 0-24 hours: 24 hours | 0.0 ± 1.15 | -0.7 ± 1.75 |
| CFB at Infusion: 25-48 hours: 48 hours | -0.6 ± 2.75 | 0.8 ± 0.98 |
| CFB at Infusion: 49-72 hours: 72 hours | -0.1 ± 2.01 | 0.3 ± 1.97 |
| CFB at Infusion: 73-96 hours: 96 hours | -0.3 ± 2.95 | -0.8 ± 2.48 |
| CFB at Infusion: 97-120 hours: 120 hours | -0.5 ± 2.62 | -1.3 ± 2.34 |
| CFB at Acute Follow-up: 121-144 hours | 0.1 ± 2.11 | 0.0 ± 1.58 |
| CFB at Acute Follow-up: 145-168 hours | -0.3 ± 2.31 | -0.8 ± 2.86 |
| CFB at Extended Follow-up: Day 8 | -0.5 ± 2.58 | -0.2 ± 1.64 |
| CFB at Extended Follow-up: Day 15 | -1.1 ± 2.90 | 0.4 ± 0.55 |
| CFB at Extended Follow-up: Day 22 | -6.9 ± 22.32 | 0.6 ± 1.52 |
| CFB at Extended Follow-up: Day 29 | -1.3 ± 3.54 | -1.2 ± 1.30 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in alanine aminotransferase levels is reported in this outcome measure.
| international units per liter (IU/L) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 48.7 ± 82.92 | 40.0 ± 32.47 |
| CFB at Infusion: 0-24 hours | 8.2 ± 23.96 | 17.0 ± 42.85 |
| CFB at Infusion: 25-48 hours | 11.0 ± 39.62 | 39.3 ± 69.34 |
| CFB at Infusion: 49-72 hours | 5.6 ± 42.77 | 36.5 ± 48.02 |
| CFB at Infusion: 73-96 hours | 1.9 ± 50.97 | 84.0 ± 124.28 |
| CFB at Infusion: 97-120 hours | 4.3 ± 64.93 | 233.3 ± 475.33 |
| CFB at Acute Follow-up: 121-144 hours | 4.6 ± 75.63 | 109.5 ± 222.80 |
| CFB at Acute Follow-up: 145-168 hours | 5.6 ± 72.25 | 48.5 ± 107.03 |
| CFB at Extended Follow-up: Day 8 | 4.9 ± 69.89 | 0.4 ± 29.80 |
| CFB at Extended Follow-up: Day 15 | -4.5 ± 85.06 | 32.2 ± 47.21 |
| CFB at Extended Follow-up: Day 22 | -3.6 ± 46.91 | 44.0 ± 65.01 |
| CFB at Extended Follow-up: Day 29 | 61.2 ± 309.38 | 374.0 ± 404.96 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in albumin levels is reported in this outcome measure.
| grams per liter (g/L) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 26.7 ± 4.87 | 21.3 ± 3.67 |
| CFB at Infusion: 0-24 hours | -0.3 ± 1.75 | -1.3 ± 3.33 |
| CFB at Infusion: 25-48 hours | -0.5 ± 1.84 | -0.7 ± 7.17 |
| CFB at Infusion: 49-72 hours | -0.2 ± 2.32 | 0.7 ± 5.28 |
| CFB at Infusion: 73-96 hours | 0.1 ± 2.26 | 3.8 ± 8.54 |
| CFB at Infusion: 97-120 hours | -0.1 ± 2.45 | 5.0 ± 6.60 |
| CFB at Acute Follow-up: 121-144 hours | 0.3 ± 2.82 | 5.3 ± 8.71 |
| CFB at Acute Follow-up: 145-168 hours | 0.6 ± 3.61 | 7.5 ± 8.96 |
| CFB at Extended Follow-up: Day 8 | 1.2 ± 4.34 | 9.2 ± 9.44 |
| CFB at Extended Follow-up: Day 15 | 2.8 ± 6.45 | 10.2 ± 6.22 |
| CFB at Extended Follow-up: Day 22 | 5.7 ± 7.46 | 9.5 ± 1.73 |
| CFB at Extended Follow-up: Day 29 | 4.8 ± 7.91 | 12.3 ± 4.04 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in aspartate aminotransferase levels is reported in this outcome measure.
| IU/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 43.8 ± 50.41 | 44.8 ± 35.87 |
| CFB at Infusion: 0-24 hours | 0.9 ± 43.24 | 18.3 ± 31.42 |
| CFB at Infusion: 25-48 hours | 7.5 ± 43.28 | 32.7 ± 30.66 |
| CFB at Infusion: 49-72 hours | -0.8 ± 40.40 | 24.5 ± 24.99 |
| CFB at Infusion: 73-96 hours | 2.4 ± 39.23 | 146.7 ± 328.43 |
| CFB at Infusion: 97-120 hours | 8.7 ± 39.62 | 854.5 ± 2056.68 |
| CFB at Acute Follow-up: 121-144 hours | 11.8 ± 35.16 | 440.3 ± 1067.48 |
| CFB at Acute Follow-up: 145-168 hours | 12.6 ± 29.27 | 264.7 ± 654.96 |
| CFB at Extended Follow-up: Day 8 | 10.8 ± 34.72 | -5.2 ± 16.63 |
| CFB at Extended Follow-up: Day 15 | 2.9 ± 33.33 | 29.0 ± 48.93 |
| CFB at Extended Follow-up: Day 22 | 15.8 ± 68.73 | 25.0 ± 55.47 |
| CFB at Extended Follow-up: Day 29 | 24.9 ± 121.92 | 1888.0 ± 3115.96 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in bicarbonate levels is reported in this outcome measure.
| millimoles per liter (mmol/L) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 22.29 ± 5.247 | 24.52 ± 4.481 |
| CFB at Infusion: 0-24 hours | 0.29 ± 2.077 | -0.85 ± 2.411 |
| CFB at Infusion: 25-48 hours | 0.68 ± 3.607 | -0.90 ± 2.205 |
| CFB at Infusion: 49-72 hours | 1.12 ± 3.252 | -0.98 ± 3.060 |
| CFB at Infusion: 73-96 hours | 1.10 ± 3.258 | -0.20 ± 3.200 |
| CFB at Infusion: 97-120 hours | 1.42 ± 4.187 | -0.83 ± 4.262 |
| CFB at Acute Follow-up: 121-144 hours | 1.68 ± 4.834 | -1.75 ± 5.511 |
| CFB at Acute Follow-up: 145-168 hours | 1.85 ± 5.119 | -2.15 ± 5.829 |
| CFB at Extended Follow-up: Day 8 | 1.27 ± 5.397 | -0.06 ± 4.463 |
| CFB at Extended Follow-up: Day 15 | 0.95 ± 5.309 | 1.14 ± 6.527 |
| CFB at Extended Follow-up: Day 22 | 1.45 ± 6.239 | 1.56 ± 5.447 |
| CFB at Extended Follow-up: Day 29 | 2.59 ± 6.432 | 0.25 ± 6.850 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in bilirubin levels is reported in this outcome measure.
| micromoles per liter (μmol/L) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 15.3900 ± 37.32086 | 6.8400 ± 7.41438 |
| CFB at Infusion: 0-24 hours | -2.8165 ± 7.32863 | 0.8550 ± 2.35707 |
| CFB at Infusion: 25-48 hours | -3.0176 ± 8.68845 | 0.0000 ± 5.72275 |
| CFB at Infusion: 49-72 hours | -1.0688 ± 3.11420 | -1.4250 ± 6.15758 |
| CFB at Infusion: 73-96 hours | 1.9237 ± 5.14423 | -0.8550 ± 5.59356 |
| CFB at Infusion: 97-120 hours | 1.3680 ± 6.27296 | 0.0000 ± 7.33508 |
| CFB at Acute Follow-up: 121-144 hours | 1.4657 ± 6.56677 | 0.5700 ± 9.34522 |
| CFB at Acute Follow-up: 145-168 hours | 3.9086 ± 10.20347 | 3.7050 ± 14.56682 |
| CFB at Extended Follow-up: Day 8 | 7.2064 ± 18.06184 | -2.0520 ± 7.49284 |
| CFB at Extended Follow-up: Day 15 | 7.6292 ± 25.00165 | -2.3940 ± 7.31512 |
| CFB at Extended Follow-up: Day 22 | 4.4197 ± 18.18369 | -0.4275 ± 5.10619 |
| CFB at Extended Follow-up: Day 29 | 26.5050 ± 69.14760 | 2.2800 ± 1.97454 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in blood urea nitrogen levels is reported in this outcome measure.
| mmol/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 4.7162 ± 2.04935 | 4.9980 ± 1.62817 |
| CFB at Infusion: 0-24 hours | 0.5752 ± 0.90926 | -0.1785 ± 0.58661 |
| CFB at Infusion: 25-48 hours | 1.2025 ± 1.55708 | -0.7140 ± 1.17322 |
| CFB at Infusion: 49-72 hours | 1.3090 ± 1.79547 | -0.8925 ± 1.16778 |
| CFB at Infusion: 73-96 hours | 1.6462 ± 2.02001 | -0.1785 ± 1.99090 |
| CFB at Infusion: 97-120 hours | 2.0160 ± 2.22925 | 0.6545 ± 2.82384 |
| CFB at Acute Follow-up: 121-144 hours | 2.1000 ± 2.37104 | 2.0825 ± 2.79663 |
| CFB at Acute Follow-up: 145-168 hours | 2.1197 ± 2.64106 | 1.9040 ± 2.79890 |
| CFB at Extended Follow-up: Day 8 | 1.8743 ± 2.74527 | 1.1424 ± 2.55448 |
| CFB at Extended Follow-up: Day 15 | 1.5396 ± 2.64507 | 0.0714 ± 2.14794 |
| CFB at Extended Follow-up: Day 22 | 2.0145 ± 5.10015 | -0.0714 ± 3.73914 |
| CFB at Extended Follow-up: Day 29 | 1.0115 ± 3.40329 | 1.3388 ± 0.79160 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in calcium levels is reported in this outcome measure.
| mmol/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 0.2037 ± 0.01153 | 0.1950 ± 0.02074 |
| CFB at Infusion: 0-24 hours | 0.0015 ± 0.00733 | 0.0021 ± 0.00732 |
| CFB at Infusion: 25-48 hours | 0.0036 ± 0.00984 | 0.0017 ± 0.01765 |
| CFB at Infusion: 49-72 hours | 0.0056 ± 0.01521 | 0.0067 ± 0.02149 |
| CFB at Infusion: 73-96 hours | 0.0078 ± 0.01522 | 0.0079 ± 0.02947 |
| CFB at Infusion: 97-120 hours | 0.0084 ± 0.01714 | 0.0117 ± 0.02493 |
| CFB at Acute Follow-up: 121-144 hours | 0.0071 ± 0.01703 | 0.0125 ± 0.02766 |
| CFB at Acute Follow-up: 145-168 hours | 0.0100 ± 0.01180 | 0.0092 ± 0.02553 |
| CFB at Extended Follow-up: Day 8 | 0.0114 ± 0.01016 | 0.0170 ± 0.01866 |
| CFB at Extended Follow-up: Day 15 | 0.0172 ± 0.01873 | 0.0170 ± 0.01681 |
| CFB at Extended Follow-up: Day 22 | 0.0202 ± 0.03017 | 0.0219 ± 0.00688 |
| CFB at Extended Follow-up: Day 29 | 0.0121 ± 0.02749 | 0.0300 ± 0.00750 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in chloride levels is reported in this outcome measure.
| mmol/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 110.0 ± 6.21 | 109.7 ± 3.72 |
| CFB at Infusion: 0-24 hours | 0.2 ± 2.82 | -3.5 ± 3.56 |
| CFB at Infusion: 25-48 hours | -0.6 ± 3.32 | -0.5 ± 5.17 |
| CFB at Infusion: 49-72 hours | -1.1 ± 3.74 | 0.5 ± 6.60 |
| CFB at Infusion: 73-96 hours | -1.6 ± 4.22 | -0.3 ± 4.63 |
| CFB at Infusion: 97-120 hours | -2.9 ± 5.07 | -2.7 ± 2.73 |
| CFB at Acute Follow-up: 121-144 hours | -2.5 ± 6.96 | -1.8 ± 4.92 |
| CFB at Acute Follow-up: 145-168 hours | -4.1 ± 7.36 | -1.2 ± 3.97 |
| CFB at Extended Follow-up: Day 8 | -4.0 ± 7.32 | -3.4 ± 5.55 |
| CFB at Extended Follow-up: Day 15 | -5.9 ± 9.02 | -4.6 ± 12.12 |
| CFB at Extended Follow-up: Day 22 | -4.1 ± 8.63 | -10.8 ± 5.81 |
| CFB at Extended Follow-up: Day 29 | -7.2 ± 6.73 | -11.0 ± 4.69 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in creatine kinase levels is reported in this outcome measure.
| IU/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 164.6 ± 297.58 | 1056.4 ± 1476.88 |
| CFB at Infusion: 0-24 hours | -5.4 ± 99.29 | 80.0 ± 343.91 |
| CFB at Infusion: 25-48 hours | -41.5 ± 204.71 | -77.0 ± 226.45 |
| CFB at Infusion: 49-72 hours | -52.8 ± 240.39 | -35.2 ± 375.74 |
| CFB at Infusion: 73-96 hours | -54.8 ± 250.36 | 187.8 ± 428.72 |
| CFB at Infusion: 97-120 hours | -69.4 ± 267.62 | 1034.6 ± 2557.56 |
| CFB at Acute Follow-up: 121-144 hours | -94.9 ± 280.01 | 864.2 ± 2487.87 |
| CFB at Acute Follow-up: 145-168 hours | -43.8 ± 269.89 | 1462.6 ± 3745.02 |
| CFB at Extended Follow-up: Day 8 | -39.5 ± 286.63 | -67.0 ± 684.14 |
| CFB at Extended Follow-up: Day 15 | -70.5 ± 293.08 | -294.5 ± 520.14 |
| CFB at Extended Follow-up: Day 22 | -108.7 ± 284.99 | -245.5 ± 217.08 |
| CFB at Extended Follow-up: Day 29 | 5.9 ± 51.57 | -356.7 ± 596.58 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in creatinine levels is reported in this outcome measure.
| μmol/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 61.8335 ± 38.35138 | 66.1527 ± 26.85624 |
| CFB at Infusion: 0-24 hours | 3.5851 ± 21.18016 | -4.2727 ± 3.96981 |
| CFB at Infusion: 25-48 hours | -0.3257 ± 17.04796 | -2.7993 ± 9.97654 |
| CFB at Infusion: 49-72 hours | -5.4513 ± 17.92081 | -5.1567 ± 13.15250 |
| CFB at Infusion: 73-96 hours | -9.0364 ± 24.69353 | 2.6520 ± 34.21891 |
| CFB at Infusion: 97-120 hours | -11.1800 ± 28.19797 | 15.1753 ± 34.57069 |
| CFB at Acute Follow-up: 121-144 hours | -10.4000 ± 30.51166 | 32.4133 ± 73.92834 |
| CFB at Acute Follow-up: 145-168 hours | -6.5748 ± 39.93224 | 37.8647 ± 103.07822 |
| CFB at Extended Follow-up: Day 8 | -9.8345 ± 34.60628 | -1.5912 ± 12.81648 |
| CFB at Extended Follow-up: Day 15 | -7.1825 ± 30.96420 | -3.3592 ± 13.75749 |
| CFB at Extended Follow-up: Day 22 | -4.6726 ± 33.58740 | -11.6688 ± 33.48365 |
| CFB at Extended Follow-up: Day 29 | 11.7867 ± 78.66321 | 0.0000 ± 23.06320 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in glucose levels is reported in this outcome measure.
| mmol/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 7.0731 ± 1.60940 | 7.1238 ± 2.48860 |
| CFB at Infusion: 0-24 hours | 0.7247 ± 1.21847 | 2.5905 ± 3.70841 |
| CFB at Infusion: 25-48 hours | 0.2542 ± 1.75414 | 0.6661 ± 1.44582 |
| CFB at Infusion: 49-72 hours | 1.0886 ± 2.99912 | 1.4155 ± 3.15690 |
| CFB at Infusion: 73-96 hours | 0.0956 ± 1.98021 | 0.2405 ± 1.85063 |
| CFB at Infusion: 97-120 hours | 0.4539 ± 1.53147 | 0.2035 ± 2.89966 |
| CFB at Acute Follow-up: 121-144 hours | 0.1437 ± 2.20744 | 0.5644 ± 1.44173 |
| CFB at Acute Follow-up: 145-168 hours | -0.1457 ± 1.83254 | -0.2683 ± 1.26456 |
| CFB at Extended Follow-up: Day 8 | -0.1596 ± 1.85981 | -1.4766 ± 2.48794 |
| CFB at Extended Follow-up: Day 15 | -0.4788 ± 1.91895 | -0.0999 ± 3.18721 |
| CFB at Extended Follow-up: Day 22 | -0.4084 ± 2.50478 | -0.1554 ± 4.07581 |
| CFB at Extended Follow-up: Day 29 | -1.1565 ± 1.79106 | -1.5959 ± 2.23900 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in lipase levels is reported in this outcome measure.
| IU/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 69.7 ± 108.56 | 48.3 ± 55.19 |
| CFB at Infusion: 0-24 hours | -13.4 ± 43.77 | 3.3 ± 3.21 |
| CFB at Infusion: 25-48 hours | -7.5 ± 34.95 | 9.3 ± 13.58 |
| CFB at Infusion: 49-72 hours | -14.4 ± 36.77 | 0.0 ± 1.73 |
| CFB at Infusion: 73-96 hours | -22.4 ± 64.01 | 18.0 ± 25.36 |
| CFB at Infusion: 97-120 hours | -20.5 ± 63.33 | -6.7 ± 22.74 |
| CFB at Acute Follow-up: 121-144 hours | -20.3 ± 91.54 | -10.7 ± 37.87 |
| CFB at Acute Follow-up: 145-168 hours | -11.7 ± 99.60 | 9.3 ± 16.92 |
| CFB at Extended Follow-up: Day 8 | -3.7 ± 100.78 | 37.0 ± 28.16 |
| CFB at Extended Follow-up: Day 15 | 24.7 ± 44.42 | 19.7 ± 100.17 |
| CFB at Extended Follow-up: Day 22 | 14.1 ± 38.25 | -15.0 ± 84.85 |
| CFB at Extended Follow-up: Day 29 | -8.3 ± 35.42 | 0.0 ± 31.00 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in magnesium levels is reported in this outcome measure.
| mmol/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 0.8969 ± 0.19546 | 0.8607 ± 0.14418 |
| CFB at Infusion: 0-24 hours | -0.0219 ± 0.11853 | -0.0441 ± 0.06638 |
| CFB at Infusion: 25-48 hours | -0.0194 ± 0.14406 | -0.0319 ± 0.11737 |
| CFB at Infusion: 49-72 hours | -0.0430 ± 0.11666 | -0.0167 ± 0.12869 |
| CFB at Infusion: 73-96 hours | -0.0374 ± 0.17268 | 0.0304 ± 0.16521 |
| CFB at Infusion: 97-120 hours | -0.0151 ± 0.22358 | 0.0754 ± 0.10859 |
| CFB at Acute Follow-up: 121-144 hours | -0.0348 ± 0.18742 | 0.0534 ± 0.13315 |
| CFB at Acute Follow-up: 145-168 hours | -0.0151 ± 0.21498 | 0.0519 ± 0.15865 |
| CFB at Extended Follow-up: Day 8 | -0.0435 ± 0.15736 | -0.0811 ± 0.16860 |
| CFB at Extended Follow-up: Day 15 | -0.0645 ± 0.15320 | -0.0494 ± 0.09381 |
| CFB at Extended Follow-up: Day 22 | -0.0564 ± 0.19263 | -0.1264 ± 0.15097 |
| CFB at Extended Follow-up: Day 29 | -0.1484 ± 0.28794 | -0.0608 ± 0.08902 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in potassium levels is reported in this outcome measure.
| mmol/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 3.76 ± 0.439 | 3.87 ± 0.301 |
| CFB at Infusion: 0-24 hours | 0.01 ± 0.515 | -0.03 ± 0.242 |
| CFB at Infusion: 25-48 hours | 0.15 ± 0.717 | -0.10 ± 0.329 |
| CFB at Infusion: 49-72 hours | 0.17 ± 0.788 | -0.37 ± 1.117 |
| CFB at Infusion: 73-96 hours | 0.05 ± 0.651 | 0.22 ± 0.601 |
| CFB at Infusion: 97-120 hours | 0.00 ± 0.446 | 0.35 ± 0.497 |
| CFB at Acute Follow-up: 121-144 hours | -0.02 ± 0.542 | 0.37 ± 0.582 |
| CFB at Acute Follow-up: 145-168 hours | -0.06 ± 0.578 | 0.75 ± 0.946 |
| CFB at Extended Follow-up: Day 8 | 0.07 ± 0.585 | 0.10 ± 0.255 |
| CFB at Extended Follow-up: Day 15 | 0.04 ± 0.734 | 0.42 ± 0.657 |
| CFB at Extended Follow-up: Day 22 | 0.12 ± 0.654 | 0.32 ± 0.683 |
| CFB at Extended Follow-up: Day 29 | 0.21 ± 0.442 | 0.38 ± 0.741 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in protein levels is reported in this outcome measure.
| g/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 56.5 ± 9.91 | 52.2 ± 7.52 |
| CFB at Infusion: 0-24 hours | 0.4 ± 1.71 | 1.0 ± 5.51 |
| CFB at Infusion: 25-48 hours | 1.1 ± 2.34 | 1.5 ± 5.92 |
| CFB at Infusion: 49-72 hours | 1.3 ± 4.08 | 4.0 ± 6.69 |
| CFB at Infusion: 73-96 hours | 2.5 ± 4.10 | 6.5 ± 5.99 |
| CFB at Infusion: 97-120 hours | 2.8 ± 2.96 | 8.8 ± 7.41 |
| CFB at Acute Follow-up: 121-144 hours | 2.5 ± 5.05 | 6.3 ± 5.89 |
| CFB at Acute Follow-up: 145-168 hours | 4.1 ± 4.87 | 7.5 ± 5.05 |
| CFB at Extended Follow-up: Day 8 | 4.3 ± 5.06 | 5.6 ± 5.68 |
| CFB at Extended Follow-up: Day 15 | 5.9 ± 9.21 | 11.0 ± 6.44 |
| CFB at Extended Follow-up: Day 22 | 6.7 ± 10.18 | 16.5 ± 8.19 |
| CFB at Extended Follow-up: Day 29 | 7.1 ± 11.56 | 20.0 ± 7.21 |
Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in sodium levels is reported in this outcome measure.
| mmol/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 140.6 ± 4.84 | 141.7 ± 4.84 |
| CFB at Infusion: 0-24 hours | 0.1 ± 2.87 | -3.8 ± 4.12 |
| CFB at Infusion: 25-48 hours | 0.7 ± 4.31 | 0.3 ± 5.72 |
| CFB at Infusion: 49-72 hours | 0.4 ± 3.88 | 1.7 ± 6.19 |
| CFB at Infusion: 73-96 hours | 0.4 ± 3.50 | 1.5 ± 3.94 |
| CFB at Infusion: 97-120 hours | 0.0 ± 4.80 | -0.5 ± 4.04 |
| CFB at Acute Follow-up: 121-144 hours | -0.3 ± 5.12 | -1.0 ± 4.60 |
| CFB at Acute Follow-up: 145-168 hours | -1.2 ± 5.64 | 0.2 ± 5.85 |
| CFB at Extended Follow-up: Day 8 | -1.8 ± 5.65 | 0.0 ± 5.79 |
| CFB at Extended Follow-up: Day 15 | -2.8 ± 5.51 | -0.4 ± 7.64 |
| CFB at Extended Follow-up: Day 22 | 0.0 ± 5.53 | -3.2 ± 4.32 |
| CFB at Extended Follow-up: Day 29 | -1.8 ± 6.34 | -4.5 ± 1.29 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in basophil levels is reported in this outcome measure.
| 10^3 cells per microliter(10^3 cells/uL) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 0.031 ± 0.0509 | 0.037 ± 0.0321 |
| CFB at Infusion: 0-24 hours | 0.013 ± 0.0308 | 0.003 ± 0.0058 |
| CFB at Infusion: 25-48 hours | -0.008 ± 0.0319 | -0.023 ± 0.0321 |
| CFB at Infusion: 49-72 hours | 0.009 ± 0.0230 | -0.007 ± 0.0208 |
| CFB at Infusion: 73-96 hours | 0.013 ± 0.0433 | -0.013 ± 0.0115 |
| CFB at Infusion: 97-120 hours | 0.004 ± 0.0662 | -0.010 ± 0.0141 |
| CFB at Acute Follow-up: 121-144 hours | 0.033 ± 0.0369 | 0.087 ± 0.1848 |
| CFB at Acute Follow-up: 145-168 hours | 0.006 ± 0.0669 | -0.017 ± 0.0153 |
| CFB at Extended Follow-up: Day 8 | 0.014 ± 0.0745 | -0.017 ± 0.0153 |
| CFB at Extended Follow-up: Day 15 | 0.031 ± 0.0366 | 0.040 ± 0.0849 |
| CFB at Extended Follow-up: Day 22 | 0.020 ± 0.0216 | 0.000 |
| CFB at Extended Follow-up: Day 29 | 0.017 ± 0.0288 | -0.005 ± 0.0071 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in basophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.
| percentage of cells | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 0.50 ± 0.707 | 0.00 ± 0.000 |
| CFB at Infusion: 0-24 hours | 0.00 | 0.00 |
| CFB at Infusion: 25-48 hours | 0.00 ± 0.000 | 1.00 |
| CFB at Infusion: 49-72 hours | 0.00 ± 0.000 | 0.00 |
| CFB at Infusion: 73-96 hours | 0.50 ± 0.707 | 1.00 |
| CFB at Infusion: 97-120 hours | 0.00 ± 0.000 | 1.00 |
| CFB at Acute Follow-up: 121-144 hours | 0.00 ± 0.000 | 0.00 |
| CFB at Acute Follow-up: 145-168 hours | 0.00 ± 0.000 | 0.00 |
| CFB at Extended Follow-up: Day 8 | 0.00 ± 0.000 | — |
| CFB at Extended Follow-up: Day 15 | -0.50 ± 0.707 | — |
| CFB at Extended Follow-up: Day 22 | 0.50 ± 0.707 | 0.00 |
| CFB at Extended Follow-up: Day 29 | 0.00 ± 0.000 | — |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in eosinophils levels is reported in this outcome measure.
| 10^3 cells/uL | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 0.3364 ± 0.42711 | 0.7433 ± 0.20108 |
| CFB at Infusion: 0-24 hours | 0.0580 ± 0.17813 | -0.2700 ± 0.24269 |
| CFB at Infusion: 25-48 hours | 0.0660 ± 0.23538 | -0.2333 ± 0.45654 |
| CFB at Infusion: 49-72 hours | -0.0911 ± 0.35069 | -0.6467 ± 0.14189 |
| CFB at Infusion: 73-96 hours | -0.0811 ± 0.36381 | -0.5867 ± 0.07095 |
| CFB at Infusion: 97-120 hours | -0.1878 ± 0.45535 | -0.4200 ± 0.41940 |
| CFB at Acute Follow-up: 121-144 hours | -0.2211 ± 0.44552 | -0.5567 ± 0.16258 |
| CFB at Acute Follow-up: 145-168 hours | -0.1643 ± 0.42177 | -0.5567 ± 0.17898 |
| CFB at Extended Follow-up: Day 8 | -0.1056 ± 0.40423 | -0.5400 ± 0.17776 |
| CFB at Extended Follow-up: Day 15 | -0.0078 ± 0.33774 | 0.0100 ± 0.26870 |
| CFB at Extended Follow-up: Day 22 | -0.0543 ± 0.42496 | -0.3000 |
| CFB at Extended Follow-up: Day 29 | -0.0229 ± 0.39982 | -0.5650 ± 0.33234 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in eosinophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.
| percentage of cells | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 3.00 ± 0.000 | 3.00 ± 0.000 |
| CFB at Infusion: 0-24 hours | 5.00 | -2.00 |
| CFB at Infusion: 25-48 hours | 0.50 ± 0.707 | 0.00 |
| CFB at Infusion: 49-72 hours | -0.50 ± 2.121 | 0.00 |
| CFB at Infusion: 73-96 hours | 0.50 ± 0.707 | -2.00 |
| CFB at Infusion: 97-120 hours | -1.00 ± 0.000 | -2.00 |
| CFB at Acute Follow-up: 121-144 hours | -1.50 ± 0.707 | -3.00 |
| CFB at Acute Follow-up: 145-168 hours | -2.00 ± 1.414 | -3.00 |
| CFB at Extended Follow-up: Day 8 | 0.50 ± 2.121 | — |
| CFB at Extended Follow-up: Day 15 | 2.00 ± 1.414 | — |
| CFB at Extended Follow-up: Day 22 | 1.00 ± 2.828 | -1.00 |
| CFB at Extended Follow-up: Day 29 | 1.50 ± 0.707 | — |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular hemoglobin concentration levels is reported in this outcome measure.
| g/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 328.4 ± 12.54 | 322.6 ± 12.54 |
| CFB at Infusion: 0-24 hours | -1.2 ± 12.52 | 1.0 ± 5.66 |
| CFB at Infusion: 25-48 hours | -4.7 ± 10.43 | 10.4 ± 12.18 |
| CFB at Infusion: 49-72 hours | -3.4 ± 7.88 | 5.4 ± 6.19 |
| CFB at Infusion: 73-96 hours | -3.6 ± 10.00 | 3.6 ± 6.35 |
| CFB at Infusion: 97-120 hours | -4.1 ± 9.33 | 1.8 ± 3.03 |
| CFB at Acute Follow-up: 121-144 hours | -6.1 ± 10.65 | -0.4 ± 2.61 |
| CFB at Acute Follow-up: 145-168 hours | -7.6 ± 10.44 | 0.4 ± 5.50 |
| CFB at Extended Follow-up: Day 8 | -7.7 ± 11.07 | -2.3 ± 9.54 |
| CFB at Extended Follow-up: Day 15 | -5.5 ± 14.28 | -0.5 ± 13.77 |
| CFB at Extended Follow-up: Day 22 | -6.9 ± 18.40 | 11.5 ± 32.25 |
| CFB at Extended Follow-up: Day 29 | -4.6 ± 16.10 | -9.3 ± 7.50 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular hemoglobin levels is reported in this outcome measure.
| femtomoles (fmol) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 1.8611 ± 0.17564 | 1.8335 ± 0.09869 |
| CFB at Infusion: 0-24 hours | 0.0110 ± 0.04180 | -0.0149 ± 0.02996 |
| CFB at Infusion: 25-48 hours | -0.0134 ± 0.03603 | 0.0261 ± 0.09580 |
| CFB at Infusion: 49-72 hours | -0.0097 ± 0.03719 | 0.0074 ± 0.03911 |
| CFB at Infusion: 73-96 hours | -0.0107 ± 0.04378 | -0.0099 ± 0.02177 |
| CFB at Infusion: 97-120 hours | -0.0164 ± 0.04034 | 0.0112 ± 0.03147 |
| CFB at Acute Follow-up: 121-144 hours | -0.0194 ± 0.03684 | 0.0099 ± 0.03582 |
| CFB at Acute Follow-up: 145-168 hours | -0.0112 ± 0.04763 | 0.0161 ± 0.03662 |
| CFB at Extended Follow-up: Day 8 | -0.0058 ± 0.04491 | 0.0155 ± 0.04927 |
| CFB at Extended Follow-up: Day 15 | -0.0087 ± 0.09182 | 0.0310 ± 0.07868 |
| CFB at Extended Follow-up: Day 22 | -0.0306 ± 0.14055 | 0.0729 ± 0.14436 |
| CFB at Extended Follow-up: Day 29 | -0.0412 ± 0.11506 | 0.0341 ± 0.07457 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular volume levels is reported in this outcome measure.
| femtoliters (fL) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 91.36 ± 7.651 | 91.50 ± 4.785 |
| CFB at Infusion: 0-24 hours | 0.68 ± 1.773 | -0.42 ± 0.950 |
| CFB at Infusion: 25-48 hours | 0.65 ± 2.202 | -0.82 ± 1.487 |
| CFB at Infusion: 49-72 hours | 0.46 ± 2.168 | -1.12 ± 1.314 |
| CFB at Infusion: 73-96 hours | 0.38 ± 2.202 | -1.04 ± 1.146 |
| CFB at Infusion: 97-120 hours | 0.47 ± 2.560 | 0.10 ± 1.954 |
| CFB at Acute Follow-up: 121-144 hours | 0.70 ± 2.362 | 0.76 ± 1.977 |
| CFB at Acute Follow-up: 145-168 hours | 1.60 ± 3.270 | 0.36 ± 1.230 |
| CFB at Extended Follow-up: Day 8 | 1.30 ± 3.507 | 1.08 ± 1.090 |
| CFB at Extended Follow-up: Day 15 | 1.20 ± 4.337 | 2.25 ± 4.124 |
| CFB at Extended Follow-up: Day 22 | 0.29 ± 5.675 | 0.75 ± 3.747 |
| CFB at Extended Follow-up: Day 29 | -0.96 ± 5.315 | 4.27 ± 1.775 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocyte levels is reported in this outcome measure.
| 10^6 cells per microliter | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 3.261 ± 0.7152 | 3.406 ± 0.5297 |
| CFB at Infusion: 0-24 hours | -0.078 ± 0.3236 | -0.022 ± 0.1816 |
| CFB at Infusion: 25-48 hours | -0.106 ± 0.4059 | -0.184 ± 0.2799 |
| CFB at Infusion: 49-72 hours | -0.162 ± 0.4112 | -0.218 ± 0.2072 |
| CFB at Infusion: 73-96 hours | -0.175 ± 0.4261 | -0.132 ± 0.3041 |
| CFB at Infusion: 97-120 hours | -0.152 ± 0.3718 | -0.158 ± 0.5079 |
| CFB at Acute Follow-up: 121-144 hours | -0.259 ± 0.4001 | -0.256 ± 0.5786 |
| CFB at Acute Follow-up: 145-168 hours | -0.199 ± 0.3819 | -0.200 ± 0.7139 |
| CFB at Extended Follow-up: Day 8 | -0.196 ± 0.4508 | -0.463 ± 0.4367 |
| CFB at Extended Follow-up: Day 15 | 0.115 ± 0.7317 | -0.133 ± 0.5821 |
| CFB at Extended Follow-up: Day 22 | 0.285 ± 0.9424 | 0.105 ± 0.3493 |
| CFB at Extended Follow-up: Day 29 | 0.607 ± 0.4754 | 0.248 ± 0.2924 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in hematocrit levels is reported in this outcome measure.
| proportion of 1.0 (in liters) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 0.2955 ± 0.05601 | 0.3110 ± 0.05443 |
| CFB at Infusion: 0-24 hours | -0.0042 ± 0.02561 | -0.0028 ± 0.01591 |
| CFB at Infusion: 25-48 hours | -0.0058 ± 0.03430 | -0.0192 ± 0.02013 |
| CFB at Infusion: 49-72 hours | -0.0123 ± 0.03371 | -0.0238 ± 0.01487 |
| CFB at Infusion: 73-96 hours | -0.0131 ± 0.03564 | -0.0142 ± 0.02860 |
| CFB at Infusion: 97-120 hours | -0.0108 ± 0.03167 | -0.0160 ± 0.04813 |
| CFB at Acute Follow-up: 121-144 hours | -0.0209 ± 0.03369 | -0.0238 ± 0.05369 |
| CFB at Acute Follow-up: 145-168 hours | -0.0135 ± 0.03487 | -0.0182 ± 0.06883 |
| CFB at Extended Follow-up: Day 8 | -0.0142 ± 0.03823 | -0.0375 ± 0.04888 |
| CFB at Extended Follow-up: Day 15 | 0.0143 ± 0.05903 | -0.0058 ± 0.05967 |
| CFB at Extended Follow-up: Day 22 | 0.0188 ± 0.06186 | 0.0128 ± 0.03157 |
| CFB at Extended Follow-up: Day 29 | 0.0516 ± 0.04241 | 0.0370 ± 0.02670 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in hemoglobin levels is reported in this outcome measure.
| g/L | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 97.3 ± 19.93 | 100.4 ± 18.28 |
| CFB at Infusion: 0-24 hours | -2.1 ± 9.96 | -0.8 ± 5.26 |
| CFB at Infusion: 25-48 hours | -3.8 ± 11.81 | -3.4 ± 4.77 |
| CFB at Infusion: 49-72 hours | -5.2 ± 12.37 | -5.8 ± 4.21 |
| CFB at Infusion: 73-96 hours | -5.8 ± 12.89 | -4.0 ± 7.97 |
| CFB at Infusion: 97-120 hours | -5.4 ± 11.54 | -4.4 ± 14.99 |
| CFB at Acute Follow-up: 121-144 hours | -8.8 ± 12.69 | -7.2 ± 16.75 |
| CFB at Acute Follow-up: 145-168 hours | -6.8 ± 12.78 | -5.6 ± 20.67 |
| CFB at Extended Follow-up: Day 8 | -6.7 ± 14.41 | -12.3 ± 12.97 |
| CFB at Extended Follow-up: Day 15 | 2.7 ± 22.10 | -2.0 ± 18.65 |
| CFB at Extended Follow-up: Day 22 | 3.8 ± 21.36 | 8.3 ± 12.58 |
| CFB at Extended Follow-up: Day 29 | 15.3 ± 14.50 | 9.5 ± 9.26 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in leukocyte levels is reported in this outcome measure.
| 10^3 cells/uL | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 11.383 ± 4.3503 | 16.538 ± 8.5348 |
| CFB at Infusion: 0-24 hours | 1.438 ± 2.5891 | -0.902 ± 2.4833 |
| CFB at Infusion: 25-48 hours | 0.186 ± 4.5526 | -3.306 ± 4.7047 |
| CFB at Infusion: 49-72 hours | -0.227 ± 6.1765 | -3.090 ± 5.5029 |
| CFB at Infusion: 73-96 hours | -0.577 ± 7.1508 | -3.798 ± 5.5846 |
| CFB at Infusion: 97-120 hours | 0.591 ± 10.3636 | -3.964 ± 5.3646 |
| CFB at Acute Follow-up: 121-144 hours | -1.002 ± 8.9938 | -1.306 ± 7.5940 |
| CFB at Acute Follow-up: 145-168 hours | -0.123 ± 10.4153 | -1.652 ± 7.3674 |
| CFB at Extended Follow-up: Day 8 | -1.145 ± 7.3294 | -2.188 ± 6.7041 |
| CFB at Extended Follow-up: Day 15 | -1.692 ± 5.0282 | -6.118 ± 7.0178 |
| CFB at Extended Follow-up: Day 22 | -1.132 ± 4.3853 | -7.248 ± 7.3886 |
| CFB at Extended Follow-up: Day 29 | -0.790 ± 6.1582 | -5.840 ± 4.6825 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in lymphocyte levels is reported in this outcome measure.
| 10^3 cells/uL | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 1.791 ± 0.8043 | 2.323 ± 0.5193 |
| CFB at Infusion: 0-24 hours | 0.213 ± 0.8923 | -0.470 ± 0.2427 |
| CFB at Infusion: 25-48 hours | 0.189 ± 1.3559 | -1.147 ± 0.9771 |
| CFB at Infusion: 49-72 hours | 0.302 ± 1.0584 | -0.640 ± 1.1037 |
| CFB at Infusion: 73-96 hours | 0.200 ± 1.1580 | -0.780 ± 0.4358 |
| CFB at Infusion: 97-120 hours | 0.428 ± 1.1946 | -0.777 ± 0.6516 |
| CFB at Acute Follow-up: 121-144 hours | 0.152 ± 0.9193 | -0.987 ± 1.0040 |
| CFB at Acute Follow-up: 145-168 hours | 0.360 ± 0.8965 | -1.013 ± 0.8799 |
| CFB at Extended Follow-up: Day 8 | 0.482 ± 0.8724 | -0.700 ± 0.6720 |
| CFB at Extended Follow-up: Day 15 | 0.392 ± 0.8363 | -1.140 ± 0.9334 |
| CFB at Extended Follow-up: Day 22 | 0.343 ± 0.6667 | -2.200 |
| CFB at Extended Follow-up: Day 29 | 0.427 ± 0.8182 | -0.845 ± 1.0677 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in lymphocytes to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.
| percentage of cells | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 10.67 ± 7.024 | 6.50 ± 7.778 |
| CFB at Infusion: 0-24 hours | -1.00 ± 0.000 | 4.00 |
| CFB at Infusion: 25-48 hours | -2.50 ± 2.121 | 8.00 |
| CFB at Infusion: 49-72 hours | 0.67 ± 5.033 | 10.00 |
| CFB at Infusion: 73-96 hours | -5.50 ± 4.950 | 6.00 |
| CFB at Infusion: 97-120 hours | -4.50 ± 6.364 | 8.00 |
| CFB at Acute Follow-up: 121-144 hours | -6.00 ± 4.243 | 1.00 |
| CFB at Acute Follow-up: 145-168 hours | -6.00 ± 2.828 | 1.00 |
| CFB at Extended Follow-up: Day 8 | -6.00 ± 1.414 | — |
| CFB at Extended Follow-up: Day 15 | -3.50 ± 3.536 | — |
| CFB at Extended Follow-up: Day 22 | 7.00 ± 4.243 | 11.00 |
| CFB at Extended Follow-up: Day 29 | 0.50 ± 2.121 | — |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in monocyte levels is reported in this outcome measure.
| 10^3 cells/uL | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 0.6182 ± 0.26966 | 1.2567 ± 0.83584 |
| CFB at Infusion: 0-24 hours | 0.2720 ± 0.39137 | 0.3470 ± 0.83703 |
| CFB at Infusion: 25-48 hours | 0.2830 ± 0.54878 | -0.1200 ± 1.05399 |
| CFB at Infusion: 49-72 hours | 0.1267 ± 0.52906 | -0.0667 ± 0.06110 |
| CFB at Infusion: 73-96 hours | 0.2978 ± 0.44409 | 0.4533 ± 0.39068 |
| CFB at Infusion: 97-120 hours | 0.2322 ± 0.42364 | 0.1300 ± 0.96016 |
| CFB at Acute Follow-up: 121-144 hours | 0.2856 ± 0.47710 | -0.1400 ± 0.34176 |
| CFB at Acute Follow-up: 145-168 hours | 0.2800 ± 0.39418 | -0.4533 ± 0.36295 |
| CFB at Extended Follow-up: Day 8 | 0.1900 ± 0.24850 | -0.2400 ± 0.72194 |
| CFB at Extended Follow-up: Day 15 | 0.1767 ± 0.41602 | -0.1100 ± 1.99404 |
| CFB at Extended Follow-up: Day 22 | 0.3029 ± 0.63746 | 1.7000 |
| CFB at Extended Follow-up: Day 29 | 0.0414 ± 0.21396 | 0.4850 ± 0.44548 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in monocytes to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.
| percentage of cells | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 7.67 ± 5.508 | 5.00 ± 4.243 |
| CFB at Infusion: 0-24 hours | 2.00 ± 0.000 | 1.00 |
| CFB at Infusion: 25-48 hours | -5.50 ± 7.778 | 13.00 |
| CFB at Infusion: 49-72 hours | -2.33 ± 0.577 | 15.00 |
| CFB at Infusion: 73-96 hours | -4.50 ± 4.950 | 8.00 |
| CFB at Infusion: 97-120 hours | -6.50 ± 9.192 | 8.00 |
| CFB at Acute Follow-up: 121-144 hours | -6.50 ± 9.192 | -1.00 |
| CFB at Acute Follow-up: 145-168 hours | -7.00 ± 9.899 | -2.00 |
| CFB at Extended Follow-up: Day 8 | -3.00 ± 8.485 | — |
| CFB at Extended Follow-up: Day 15 | -4.50 ± 6.364 | — |
| CFB at Extended Follow-up: Day 22 | -2.50 ± 4.950 | 0.00 |
| CFB at Extended Follow-up: Day 29 | -5.50 ± 9.192 | — |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in neutrophil levels is reported in this outcome measure.
| 10^3 cells/uL | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 7.957 ± 4.1505 | 13.863 ± 8.8017 |
| CFB at Infusion: 0-24 hours | 0.152 ± 2.4078 | -0.043 ± 1.7435 |
| CFB at Infusion: 25-48 hours | -0.552 ± 3.1815 | -0.783 ± 2.9957 |
| CFB at Infusion: 49-72 hours | -1.406 ± 3.4517 | -0.167 ± 7.0002 |
| CFB at Infusion: 73-96 hours | -1.727 ± 3.6351 | -1.620 ± 6.0920 |
| CFB at Infusion: 97-120 hours | -0.743 ± 3.3970 | -2.653 ± 5.7315 |
| CFB at Acute Follow-up: 121-144 hours | -1.848 ± 4.2871 | -4.247 ± 6.7336 |
| CFB at Acute Follow-up: 145-168 hours | -1.440 ± 4.1338 | -3.517 ± 7.8465 |
| CFB at Extended Follow-up: Day 8 | -1.731 ± 4.4360 | -1.953 ± 7.7993 |
| CFB at Extended Follow-up: Day 15 | -2.372 ± 4.3518 | -9.825 ± 6.9650 |
| CFB at Extended Follow-up: Day 22 | -0.877 ± 3.2310 | -10.645 ± 7.9832 |
| CFB at Extended Follow-up: Day 29 | -1.590 ± 2.6196 | -6.323 ± 3.8800 |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in neutrophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.
| percentage of cells | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 75.67 ± 11.240 | 71.00 ± 8.485 |
| CFB at Infusion: 0-24 hours | -3.50 ± 9.192 | 19.00 |
| CFB at Infusion: 25-48 hours | 5.00 ± 5.657 | 6.00 |
| CFB at Infusion: 49-72 hours | 5.67 ± 10.504 | 3.00 |
| CFB at Infusion: 73-96 hours | 11.00 ± 11.314 | 2.00 |
| CFB at Infusion: 97-120 hours | 13.50 ± 17.678 | 9.00 |
| CFB at Acute Follow-up: 121-144 hours | 15.00 ± 14.142 | 31.00 |
| CFB at Acute Follow-up: 145-168 hours | 11.00 ± 8.485 | 25.00 |
| CFB at Extended Follow-up: Day 8 | 11.00 ± 11.314 | — |
| CFB at Extended Follow-up: Day 15 | 7.50 ± 9.192 | — |
| CFB at Extended Follow-up: Day 22 | -4.00 ± 7.071 | -10.00 |
| CFB at Extended Follow-up: Day 29 | 6.50 ± 14.849 | — |
Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in platelet levels is reported in this outcome measure.
| 10^3 cells/uL | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 260.76 ± 95.417 | 284.20 ± 80.707 |
| CFB at Infusion: 0-24 hours | 2.93 ± 68.821 | 21.40 ± 40.265 |
| CFB at Infusion: 25-48 hours | 17.38 ± 92.854 | 34.40 ± 69.263 |
| CFB at Infusion: 49-72 hours | 21.59 ± 109.995 | 58.00 ± 95.533 |
| CFB at Infusion: 73-96 hours | 31.92 ± 112.963 | 77.80 ± 89.461 |
| CFB at Infusion: 97-120 hours | 57.49 ± 125.277 | 64.80 ± 101.043 |
| CFB at Acute Follow-up: 121-144 hours | 63.04 ± 138.415 | 61.80 ± 106.767 |
| CFB at Acute Follow-up: 145-168 hours | 81.98 ± 141.650 | 50.80 ± 130.555 |
| CFB at Extended Follow-up: Day 8 | 58.33 ± 120.436 | 48.75 ± 136.231 |
| CFB at Extended Follow-up: Day 15 | 153.89 ± 166.919 | 87.25 ± 177.265 |
| CFB at Extended Follow-up: Day 22 | 86.35 ± 204.827 | 49.75 ± 75.292 |
| CFB at Extended Follow-up: Day 29 | 25.76 ± 118.996 | 56.75 ± 112.512 |
ECG measures included heart rate, PR interval, QT interval, QRS duration and QTc interval. CFB in heart rate is reported in this outcome measure.
| beats/min | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 84.3 ± 13.31 | 84.3 ± 19.64 |
| CFB at Infusion: 0-24 hours | -1.4 ± 16.87 | -6.8 ± 8.54 |
| CFB at Infusion: 25-48 hours | -0.9 ± 16.58 | -1.2 ± 6.85 |
| CFB at Infusion: 49-72 hours | 10.9 ± 21.74 | -6.5 ± 22.28 |
| CFB at Infusion: 73-96 hours | 9.7 ± 15.49 | 7.7 ± 18.48 |
| CFB at Infusion: 97-120 hours | 15.9 ± 15.37 | 7.0 ± 19.62 |
| CFB at Acute Follow-up: 121-144 hours | 13.2 ± 14.25 | 11.7 ± 22.76 |
| CFB at Acute Follow-up: 145-168 hours | 16.6 ± 16.91 | 17.0 ± 26.47 |
| CFB at Extended Follow-up: Day 8 | 19.2 ± 16.00 | 5.5 ± 22.87 |
| CFB at Extended Follow-up: Day 15 | 15.0 ± 23.09 | 5.5 ± 13.13 |
| CFB at Extended Follow-up: Day 22 | 13.8 ± 20.71 | 4.3 ± 26.73 |
| CFB at Extended Follow-up: Day 29 | 8.6 ± 13.60 | 7.0 ± 31.19 |
ECG measures included heart rate, PR interval, QT interval, QRS duration and QTc interval. CFB in PR interval, QT interval, QRS duration and QTc interval is reported in this outcome measure.
| milliseconds (msec) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| PR interval: Baseline | 151.0 (118 to 192) | 151.0 (132 to 182) |
| PR interval: CFB at Infusion: 0-24 hours | 2.0 (-40 to 10) | -2.0 (-16 to 18) |
| PR interval: CFB at Infusion: 25-48 hours | 3.0 (-40 to 148) | 3.0 (-4 to 15) |
| PR interval: CFB at Infusion: 49-72 hours | -13.0 (-42 to 16) | -2.0 (-8 to 18) |
| PR interval: CFB at Infusion: 73-96 hours | -2.0 (-22 to 22) | -4.0 (-6 to 7) |
| PR interval: CFB at Infusion: 97-120 hours | -12.0 (-32 to 68) | 2.0 (-22 to 26) |
| PR interval: CFB at Acute Follow-up: 121-144 hours | -8.0 (-25 to 23) | 3.5 (-28 to 12) |
| PR interval: CFB at Acute Follow-up: 145-168 hours | -11.0 (-38 to 14) | -2.0 (-26 to 24) |
| PR interval: CFB at Extended Follow-up: Day 8 | -10.0 (-30 to 4) | 0.0 (-20 to 2) |
| PR interval: CFB at Extended Follow-up: Day 15 | 0.0 (-54 to 26) | 4.0 (-16 to 18) |
| PR interval: CFB at Extended Follow-up: Day 22 | 2.0 (-26 to 36) | -6.5 (-40 to 10) |
| PR interval: CFB at Extended Follow-up: Day 29 | 2.0 (-20 to 14) | -8.0 (-18 to 22) |
| QRS Interval: Baseline | 85.0 (66 to 118) | 78.0 (40 to 100) |
| QRS Interval: CFB at Infusion: 0-24 hours | 1.0 (-12 to 14) | 1.5 (-4 to 20) |
| QRS Interval: CFB at Infusion: 25-48 hours | 0.0 (-14 to 40) | -1.0 (-8 to 6) |
| QRS Interval: CFB at Infusion: 49-72 hours | -3.0 (-20 to 6) | 2.0 (-2 to 5) |
| QRS Interval: CFB at Infusion: 73-96 hours | 0.0 (-16 to 18) | 0.0 (-6 to 20) |
| QRS Interval: CFB at Infusion: 97-120 hours | -4.0 (-32 to 14) | 0.0 (-14 to 20) |
| QRS Interval: CFB at Acute Follow-up: 121-144 hours | -2.0 (-32 to 8) | 0.0 (-14 to 20) |
| QRS Interval: CFB at Acute Follow-up: 145-168 hours | -6.0 (-28 to 16) | -3.0 (-94 to 20) |
| QRS Interval: CFB at Extended Follow-up: Day 8 | -2.0 (-28 to 0) | -3.5 (-16 to 0) |
| QRS Interval: CFB at Extended Follow-up: Day 15 | -5.0 (-47 to 6) | 2.0 (-2 to 40) |
| QRS Interval: CFB at Extended Follow-up: Day 22 | -4.0 (-26 to 6) | -1.0 (-4 to 20) |
| QRS Interval: CFB at Extended Follow-up: Day 29 | 2.0 (-26 to 12) | 5.0 (-4 to 40) |
| QT Interval: Baseline | 363.0 (304 to 476) | 372.0 (280 to 462) |
| QT Interval: CFB at Infusion: 0-24 hours | 19.5 (-84 to 200) | 24.5 (-26 to 49) |
| QT Interval: CFB at Infusion: 25-48 hours | 19.5 (-102 to 236) | 3.0 (-40 to 30) |
| QT Interval: CFB at Infusion: 49-72 hours | 1.0 (-168 to 238) | -14.0 (-66 to 144) |
| QT Interval: CFB at Infusion: 73-96 hours | -4.0 (-62 to 128) | 0.0 (-76 to 118) |
| QT Interval: CFB at Infusion: 97-120 hours | -34.0 (-164 to 72) | -36.0 (-102 to 66) |
| QT Interval: CFB at Acute Follow-up: 121-144 hours | -28.0 (-168 to 238) | -32.0 (-126 to 40) |
| QT Interval: CFB at Acute Follow-up: 145-168 hours | -32.0 (-164 to 74) | -34.0 (-156 to 18) |
| QT Interval: CFB at Extended Follow-up: Day 8 | -36.0 (-186 to 42) | -35.0 (-138 to -6) |
| QT Interval: CFB at Extended Follow-up: Day 15 | -32.0 (-176 to 72) | -8.0 (-116 to 16) |
| QT Interval: CFB at Extended Follow-up: Day 22 | -28.0 (-132 to 51) | -22.0 (-102 to 24) |
| QT Interval: CFB at Extended Follow-up: Day 29 | -28.0 (-132 to 29) | -63.0 (-96 to 80) |
| QTc Interval: Baseline | 435.5 (321 to 531) | 438.5 (393 to 454) |
| QTc Interval: CFB at Infusion: 0-24 hours | 7.5 (-55 to 219) | 7.0 (-58 to 42) |
| QTc Interval: CFB at Infusion: 25-48 hours | 11.5 (-49 to 277) | -12.5 (-59 to 29) |
| QTc Interval: CFB at Infusion: 49-72 hours | 3.5 (-103 to 275) | -14.0 (-38 to 36) |
| QTc Interval: CFB at Infusion: 73-96 hours | 8.0 (-30 to 145) | -13.5 (-41 to 152) |
| QTc Interval: CFB at Infusion: 97-120 hours | -2.0 (-88 to 106) | -17.0 (-38 to 43) |
| QTc Interval: CFB at Acute Follow-up: 121-144 hours | -12.0 (-87 to 319) | -9.0 (-31 to 10) |
| QTc Interval: CFB at Acute Follow-up: 145-168 hours | -4.0 (-96 to 93) | -17.5 (-52 to 15) |
| QTc Interval: CFB at Extended Follow-up: Day 8 | -15.0 (-111 to 83) | -54.5 (-86 to 14) |
| QTc Interval: CFB at Extended Follow-up: Day 15 | 2.0 (-104 to 71) | -6.5 (-50 to 3) |
| QTc Interval: CFB at Extended Follow-up: Day 22 | -8.5 (-57 to 51) | -33.5 (-37 to -14) |
| QTc Interval: CFB at Extended Follow-up: Day 29 | -2.0 (-72 to 51) | -19.0 (-51 to 23) |
Prior AEDs and Pressors are those medications that ended before the initiation of SAGE-547 infusion.
| Participants | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Number of Participants With Prior Anti-epileptic Drugs (AEDs) and Pressors Usage | 16 | 4 |
Relapse of participants is defined as successfully weaning from a continuous IV third-line agent but subsequent requirement of re-initiation of a third-line agent following conclusion of SAGE-547 treatment.
| Participants | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Number of Participants With Relapse - Re-Initiation of Third-Line Agent | 5 | 1 |
A responder was defined as a participant for whom it was not required to re-initiate continuous IV third-line therapy for refractory seizure control during the administration of SAGE-547 at the maintenance dose (prior to SAGE-547 taper infusion).
| Participants | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Number of Participants With Treatment Response (Treatment Responders) | 13 | 4 |
Duration of response was defined as the time from the stop date/time of SAGE-547 maintenance to re-initiation of a third-line agent. If no re-initiation of a third-line agent was required, duration of response was not estimable and censored at Day 29 or death date, whichever occurred first. Kaplan-Meier method was used for the analysis.
| days | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Duration of Response | NA (NA to NA) | NA (NA to NA) |
| nanograms per milliliter (ng/mL) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of SAGE-547 | 144.24 ± 65.263 | 200.82 ± 71.000 |
| hours | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Time to Attain Maximum Observed Plasma Concentration (Tmax) of SAGE-547 | 1.010 (0.92 to 96.00) | 60.150 (0.93 to 118.52) |
| hour*nanograms per milliliter (h*ng/mL) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Areas Under the Plasma SAGE-547 Concentration Time Curves From the Start of the Infusion Until the Time to the Last Sample (AUClast) | 7677.6 ± 2668.06 | 14260.0 ± 5048.01 |
| h*ng/mL | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Area Under the Plasma SAGE-547 Concentration-Time Curve in a 24 Hour Period (AUC24) | 1590.3 ± 524.58 | 2728.3 ± 1010.14 |
| h*ng/mL | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Area Under the Plasma SAGE-547 Concentration-Time Curve (AUC1-96) | 6290.6 ± 2080.04 | 10801.7 ± 4006.70 |
| ng/mL | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Average Plasma Concentration (Cav) of SAGE-547 | 66.22 ± 21.929 | 113.62 ± 42.079 |
Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.
| liters per hour per kilogram (L/h/kg) | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Plasma Clearance (CL) of SAGE-547 | 1.3999 ± 0.54525 | 1.2487 ± 0.65351 |
The mRS-9Q is a commonly used scale to determine disability and functional dependence due to neurological insult such as a stroke. It is a shortened version consisting of 9 questions. The score was categorized on the scale of 0 to 5 (0 = No symptoms, 1 = No significant disability, able to carry out all usual activities, despite some symptoms, 2 = Slight disability, able to look after own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability, requires some help, but able to walk unassisted, 4 = Moderately severe disability, unable to attend to own bodily needs without assistance or unable to walk unassisted, and 5 = Severe disability, requires constant nursing care and attention, bedridden). Higher scores indicated worsening of symptoms.
| score on a scale | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 5.0 ± 0.00 | 5.0 ± 0.00 |
| CBF at Infusion: 49-72 hours | 0.0 ± 0.00 | 0.0 ± 0.00 |
| CFB at Infusion: 73-96 hours | 0.0 ± 0.00 | 0.0 ± 0.00 |
| CFB at Extended Follow-up: Day 8 | -0.1 ± 0.26 | 0.0 ± 0.00 |
| CFB at Extended Follow-up: Day 15 | -0.1 ± 0.35 | -0.3 ± 0.50 |
| CFB at Extended Follow-up: Day 22 | -0.4 ± 0.74 | -0.5 ± 0.58 |
| CFB at Extended Follow-up: Day 29 | -0.9 ± 1.50 | -1.0 ± 1.41 |
The CGI-Severity (CGI-S) scale employs a 7-point Likert scale to assess the severity of participant's current illness state. Clinician responded to a question "Considering your total clinical experience with this particular population, how mentally ill is your patient at this time?" on the following scores: 1 = Normal, not at all ill, 2 = Borderline ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, and 7 = Among the most extremely ill, where higher score = more affected.
| score on a scale | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 6.9 ± 0.25 | 6.8 ± 0.41 |
| CFB at Extended Follow-up: Day 8 | -1.1 ± 1.06 | -1.2 ± 1.30 |
| CFB at Extended Follow-up: Day 15 | -2.3 ± 1.22 | -1.8 ± 1.79 |
| CFB at Extended Follow-up: Day 22 | -2.7 ± 1.63 | -2.4 ± 1.82 |
| CFB at Extended Follow-up: Day 29 | -3.0 ± 1.96 | -2.8 ± 2.39 |
The CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse; where higher scores indicated worst outcomes. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions.
| score on a scale | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Infusion: 0-24 hours | 4.0 ± 0.37 | 4.0 ± 0.00 |
| Infusion: 25-48 hours | 4.0 ± 0.52 | 4.5 ± 0.84 |
| Infusion: 49-72 hours | 3.6 ± 0.81 | 3.6 ± 0.89 |
| Infusion: 73-96 hours | 3.1 ± 0.81 | 3.7 ± 1.37 |
| Infusion: 97-120 hours | 2.9 ± 0.81 | 3.0 ± 1.10 |
| Acute Follow-up: 121-144 hours | 3.3 ± 1.30 | 4.0 ± 1.41 |
| Acute Follow-up: 145-168 hours | 3.2 ± 1.52 | 3.2 ± 1.92 |
| Extended Follow-up: Day 8 | 2.9 ± 1.53 | 2.8 ± 1.10 |
| Extended Follow-up: Day 15 | 2.2 ± 1.21 | 2.4 ± 1.14 |
| Extended Follow-up: Day 22 | 2.3 ± 1.58 | 2.6 ± 1.95 |
| Extended Follow-up: Day 29 | 2.6 ± 1.89 | 2.4 ± 2.61 |
The Glasgow Coma Scale is divided into three components which are scored separately: ocular response (assessment 1-4 points), motor response (assessment 1-6 points), verbal response (evaluation of 1-5 points). Scores for each component are added together to get the total score that will range between a minimum of 3 points (which corresponds to a participant who does not open his/her eyes and no motor response to stimulation or verbal response) and a maximum value of 15 points (corresponding to a participant with open eyes, obeying orders and maintaining a consistent language). It has been considered that the GCS score between 15 and 13 points corresponds to a slight alteration of consciousness, a score of 12-9 points with moderate impairment and 8 points or less with a serious deterioration in level of consciousness.
| score on a scale | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | 3.9 ± 1.88 | 3.5 ± 1.22 |
| CFB at Infusion: 0-24 hours | -0.4 ± 1.26 | -0.2 ± 0.45 |
| CFB at Infusion: 25-48 hours | -0.6 ± 1.63 | -0.5 ± 1.22 |
| CFB at Infusion: 49-72 hours | 0.9 ± 2.21 | 1.4 ± 1.34 |
| CFB at Infusion: 73-96 hours | 1.1 ± 2.16 | 1.3 ± 2.42 |
| CFB at Infusion: 97-120 hours | 2.4 ± 3.16 | 3.0 ± 3.69 |
| CFB at Acute Follow-up: 121-144 hours | 3.3 ± 3.30 | 3.3 ± 3.93 |
| CFB at Acute Follow-up: 145-168 hours | 3.9 ± 3.98 | 5.0 ± 4.90 |
| CFB at Extended Follow-up: Day 8 | 3.9 ± 4.53 | 5.0 ± 4.90 |
| CFB at Extended Follow-up: Day 15 | 6.7 ± 4.73 | 5.4 ± 5.27 |
| CFB at Extended Follow-up: Day 22 | 6.9 ± 4.99 | 6.4 ± 4.83 |
| CFB at Extended Follow-up: Day 29 | 6.1 ± 5.70 | 7.4 ± 4.67 |
The RASS was an assessment of agitation and sedation in hospitalized participants, using a 10 point scale (ranged from -5 to +4), where, -5 = Unarousable, -4 = Deep sedation, -3 = Moderate sedation, -2 = Light sedation, -1 = Drowsy, 0 = Alert and calm, +1 = Restless, +2 = Agitated, +3 = Very agitated and +4 = Combative. Lower scores signify higher levels of sedation and higher scores signify heightened agitation. Participant in a calm and alert state would score a 0.
| score on a scale | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Baseline | -4.8 ± 0.54 | -4.8 ± 0.41 |
| CFB at Infusion: 0-24 hours | -0.1 ± 0.25 | 0.0 ± 0.00 |
| CFB at Infusion: 25-48 hours | -0.1 ± 0.44 | 0.0 ± 0.00 |
| CFB at Infusion: 49-72 hours | 0.5 ± 1.32 | 0.8 ± 1.30 |
| CFB at Infusion: 73-96 hours | 0.9 ± 1.41 | 0.7 ± 1.21 |
| CFB at Infusion: 97-120 hours | 1.4 ± 1.59 | 1.3 ± 1.75 |
| CFB at Acute Follow-up: 121-144 hours | 2.0 ± 1.97 | 1.3 ± 1.97 |
| CFB at Acute Follow-up: 145-168 hours | 2.3 ± 2.24 | 1.4 ± 1.67 |
| CFB at Extended Follow-up: Day 8 | 2.3 ± 2.16 | 2.4 ± 2.61 |
| CFB at Extended Follow-up: Day 15 | 3.3 ± 1.79 | 2.2 ± 1.92 |
| CFB at Extended Follow-up: Day 22 | 3.4 ± 1.91 | 2.8 ± 2.17 |
| CFB at Extended Follow-up: Day 29 | 3.0 ± 2.22 | 2.8 ± 2.17 |
Survival time was defined as duration of survival from screening up to Day 29.
| Participants | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| Number of Participants Who Survived | 13 | 5 |
Collected over Up to 29 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SAGE-547 Standard Dose | 5/19 (26.3%) | 14/19 (73.7%) | 15/19 (78.9%) |
| SAGE-547 High Dose | 1/6 (16.7%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| SepsisInfections and infestations | 1/19 | 1/6 |
| PeritonitisInfections and infestations | 0/19 | 1/6 |
| HypotensionVascular disorders | 0/19 | 1/6 |
| Multi-organ failureGeneral disorders | 0/19 | 1/6 |
| Metabolic acidosisMetabolism and nutrition disorders | 0/19 | 1/6 |
| Renal failure acuteRenal and urinary disorders | 1/19 | 1/6 |
| Cardiac arrestCardiac disorders | 0/19 | 1/6 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/19 | 1/6 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/19 | 0/6 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/19 | 0/6 |
| Event | SAGE-547 Standard Dose | SAGE-547 High Dose |
|---|---|---|
| HypotensionVascular disorders | 0/19 | 3/6 |
| Urinary tract infectionInfections and infestations | 1/19 | 2/6 |
| Blood creatine phosphokinase increasedInvestigations | 0/19 | 2/6 |
| Lipase increasedInvestigations | 0/19 | 2/6 |
| HypertensionVascular disorders | 1/19 | 2/6 |
| Skin disorderSkin and subcutaneous tissue disorders | 0/19 | 2/6 |
| Sinus tachycardiaCardiac disorders | 1/19 | 2/6 |
| Fungal skin infectionInfections and infestations | 1/19 | 1/6 |
| Oral candidiasisInfections and infestations | 1/19 | 1/6 |
| PneumoniaInfections and infestations | 1/19 | 1/6 |
Safety population included all participants who were initiated with an infusion of SAGE-547.
| Age, Continuous(years) | SAGE-547 Standard Dose | SAGE-547 High Dose | Total |
|---|---|---|---|
| Mean | 49.3 ± 18.98 | 42.3 ± 22.11 | 47.6 ± 19.52 |
| Sex: Female, Male(Participants) | SAGE-547 Standard Dose | SAGE-547 High Dose | Total |
|---|---|---|---|
| Female | 8 | 1 | 9 |
| Male | 11 | 5 | 16 |
| Ethnicity (NIH/OMB)(Participants) | SAGE-547 Standard Dose | SAGE-547 High Dose | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 18 | 5 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SAGE-547 Standard Dose | SAGE-547 High Dose | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 15 | 4 | 19 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Ran from Mar 2014 to primary completion in May 2015, 13 months.
Results were first posted in May 2022, 7 years after primary completion. A results delay was requested in Apr 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexanolone
Supernus Pharmaceuticals, Inc. →